Literature DB >> 15619041

Multiple endocrine neoplasia type 1 in end-stage renal failure.

Hodaka Suzuki1, Tetsuo Katoh, Yutaka Sakuma, Mitsuo Takahashi, Koichi Asahi, Shigeatsu Hashimoto, Shinji Kosugi, Shinichi Suzuki, Seiichi Takenoshita, Tsuyoshi Watanabe.   

Abstract

A 59-year-old woman with chronic renal failure due to type 2 diabetes mellitus (DM) is presented. Her father and a brother had a history of brain tumor. Her blood urea nitrogen and serum creatinine levels were 102 mg/dl and 4.5 mg/dl, respectively. Her serum Ca(2+) and Pi were within the normal range (9.4 mg/dl and 5.4 mg/dl, respectively). Her intact parathyroid hormone (PTH) level was 1 730 000 pg/ml. A (99m)Tc-methoxy-isobutylisonitrile scintigraphy showed high uptake in three parathyroid glands. A magnetic resonance image showed microadenoma in the pituitary gland. The serum gastrin level was high. Genetic examination revealed a mutation of the MEN1 gene (894-9 G --> A). From these findings, she was diagnosed with multiple endocrine neoplasia (MEN) type 1. Subsequently, a parathyroidectomy was performed successfully, a parathyroid gland was transplanted to her right forearm, and her serum Ca(2+) level was controlled at 8.5-9.0 mg/dl. It is very important to identify MEN1 if an end-stage renal disease (ESRD) patient has hyperparathyroidism with multigland involvement. Examination of the MEN1 gene may be valuable to make an accurate diagnosis and choose the appropriate therapy in some ESRD patients with hyperparathyroidism.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619041     DOI: 10.1007/s10157-004-0318-7

Source DB:  PubMed          Journal:  Clin Exp Nephrol        ISSN: 1342-1751            Impact factor:   2.801


  1 in total

1.  Challenging Differential Diagnosis of Hypergastremia and Hyperglucagonemia with Chronic Renal Failure: Report of a Case with Multiple Endocrine Neoplasia Type 1.

Authors:  Takaaki Murakami; Takeshi Usui; Yuji Nakamoto; Akio Nakajima; Yuki Mochida; Sumio Saito; Takahiro Shibayama; Nobuhisa Yamazaki; Tomonobu Hatoko; Tomoko Kato; Shin Yonemitsu; Seiji Muro; Shogo Oki
Journal:  Intern Med       Date:  2017-06-01       Impact factor: 1.271

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.